FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates

Company Performance - FibroGen reported a quarterly loss of $3.38 per share, which was worse than the Zacks Consensus Estimate of a loss of $2.25, and an improvement from a loss of $4 per share a year ago, indicating a surprise of -50.22% [1] - The company posted revenues of $1.35 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 53.52%, and a significant decline from year-ago revenues of $50.64 million [2] - Over the last four quarters, FibroGen has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Performance - FibroGen shares have declined approximately 34.2% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current Zacks Rank for FibroGen is 4 (Sell), indicating expectations for the stock to underperform the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$2.38 on revenues of $2.9 million, and for the current fiscal year, it is -$3.25 on revenues of $12.7 million [7] - The earnings outlook and estimate revisions trend for FibroGen were unfavorable prior to the earnings release, which may impact future stock movements [6][5] Industry Context - The Medical - Drugs industry, to which FibroGen belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a relatively strong industry performance [8] - Another company in the same industry, AIM ImmunoTech Inc., is expected to report a quarterly loss of $8.00 per share, reflecting a year-over-year change of -166.7% [9]